Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

145 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort study.
van der Kooij MK, Joosse A, Suijkerbuijk KPM, Aarts MJB, van den Berkmortel FWPJ, Blank CU, Boers-Sonderen MJ, van den Eertwegh AJM, de Groot JWB, Haanen JBAG, Hospers GAP, Piersma D, van Rijn RS, van der Veldt AAM, Vreugdenhil G, Westgeest HM, Wouters MWJM, Dekkers OM, Kapiteijn E. van der Kooij MK, et al. Among authors: suijkerbuijk kpm. Br J Cancer. 2023 Mar;128(5):707-710. doi: 10.1038/s41416-022-02088-8. Epub 2022 Dec 23. Br J Cancer. 2023. PMID: 36564561 Free PMC article. No abstract available.
Oxytocin: bringing magic into nipple aspiration.
Suijkerbuijk KP, van der Wall E, van Diest PJ. Suijkerbuijk KP, et al. Ann Oncol. 2007 Oct;18(10):1743-4. doi: 10.1093/annonc/mdm435. Epub 2007 Sep 4. Ann Oncol. 2007. PMID: 17785758 Free article. No abstract available.
Development and Validation of Nomograms to Predict Local, Regional, and Distant Recurrence in Patients With Thin (T1) Melanomas.
El Sharouni MA, Ahmed T, Varey AHR, Elias SG, Witkamp AJ, Sigurdsson V, Suijkerbuijk KPM, van Diest PJ, Scolyer RA, van Gils CH, Thompson JF, Blokx WAM, Lo SN. El Sharouni MA, et al. Among authors: suijkerbuijk kpm. J Clin Oncol. 2021 Apr 10;39(11):1243-1252. doi: 10.1200/JCO.20.02446. Epub 2021 Feb 18. J Clin Oncol. 2021. PMID: 33600211
Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
Larkin J, Chmielowski B, Lao CD, Hodi FS, Sharfman W, Weber J, Suijkerbuijk KPM, Azevedo S, Li H, Reshef D, Avila A, Reardon DA. Larkin J, et al. Among authors: suijkerbuijk kpm. Oncologist. 2017 Jun;22(6):709-718. doi: 10.1634/theoncologist.2016-0487. Epub 2017 May 11. Oncologist. 2017. PMID: 28495807 Free PMC article.
Comparing survival predicted by the diagnosis-specific Graded Prognostic Assessment (DS-GPA) to actual survival in patients with 1-10 brain metastases treated with stereotactic radiosurgery.
Nagtegaal SHJ, Claes A, Suijkerbuijk KPM, Schramel FMNH, Snijders TJ, Verhoeff JJC. Nagtegaal SHJ, et al. Among authors: suijkerbuijk kpm. Radiother Oncol. 2019 Sep;138:173-179. doi: 10.1016/j.radonc.2019.06.033. Epub 2019 Jul 11. Radiother Oncol. 2019. PMID: 31302392
Development and validation of risk calculators for people with "thin" melanomas on their skin to predict the likelihood that their cancer will return: a plain language summary of publication.
Sharouni ME, Lo SN, Varey AH, Elias SG, Witkamp AJ, Sigurdsson V, Suijkerbuijk KP, van Diest PJ, van Gils CH, Blokx WA, Scolyer RA, Thompson JF. Sharouni ME, et al. Future Oncol. 2023 Jan;19(2):97-102. doi: 10.2217/fon-2022-0525. Epub 2023 Feb 10. Future Oncol. 2023. PMID: 36762595 Free article. Review.
145 results